Santhera Pharmaceuticals AG, of Liestal, Switzerland, said it submitted briefing material and a meeting request to the FDA to discuss the filing of a new drug application for Raxone (idebenone) for the treatment of Duchenne muscular dystrophy (DMD) patients not taking concomitant glucocorticoids.